Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Cyclopharm Limited ( (AU:CYC) ) has provided an announcement.
Cyclopharm Limited has secured a five-year Federal Supply Schedule agreement with the US Veterans Health Administration, marking a significant expansion of its Technegas product within the US federal healthcare system. This agreement simplifies procurement processes and ensures a consistent supply of Technegas, strengthening Cyclopharm’s position in the US market despite uncertainties in healthcare funding policies.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that provides nuclear medicine solutions to the global medical community. The company’s primary product, Technegas, is used for functional lung ventilation imaging and has applications in diagnosing various pulmonary conditions.
YTD Price Performance: -17.41%
Average Trading Volume: 139,604
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$151.1M
For detailed information about CYC stock, go to TipRanks’ Stock Analysis page.